B
YARW

Bailard’s Yarrow Bioscience YARW Stock Holding History

Bailard’s Portfolio YARW Stock Details YARW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-155
Closed -$91K – 803
2022
Q1 		$91K Buy
+155
New +$92.1K ﹤0.01% 698

Other funds holding YARW

DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
TSS
Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return
CAN
Cetera Advisor Networks El Segundo, California $20.2B AUM 22.31% 1-Year Est. Return

Bailard's YARW Position: Q2 2022 in Review

Bailard sold out of Yarrow Bioscience (YARW) in Q2 2022, closing a stake of 155 shares — an estimated $91K sold.

Bailard first reported a position in YARW in Q1 2022 and held it in 1 quarter. The position peaked at $91K in Q1 2022. 37 funds tracked by Wall St. Rank hold YARW as of Q2 2022.

  • Bailard reported no remaining Yarrow Bioscience position as of Q2 2022 after selling out during the quarter.
  • Bailard sold 155 Yarrow Bioscience shares in Q2 2022, an estimated $91K.
  • Bailard first reported a position in Yarrow Bioscience in Q1 2022 and held it in 1 quarter.
  • Bailard's Yarrow Bioscience position peaked at $91K in Q1 2022.
  • 37 funds tracked by Wall St. Rank held Yarrow Bioscience as of Q2 2022.

Based on Bailard's 13F filing for Q2 2022, filed 27 Jul 2022.